The chaperone-based therapeutics market is projected to grow from USD 1,663.5 million in 2026 to USD 5,354.1 million by 2036, at a CAGR of 12.4%. Pharmacological chaperones will dominate with a 78.0% market share, while lysosomal storage disorders will lead the applications segment with a 54.0% share.